This observational study will assess the efficacy and safety of MabThera (rituximab) in combination with methotrexate in patients with active refractory rheumatoid arthritis who have failed to respond to a single course of anti-TNF therapy in routine clinical practice. Data will be collected from patients for 12 months after the first dose of MabThera or a minimum of 6 months following a re-treatment course.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01283399?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
